Objective:
To determine if docosahexaenoic acid (DHA) safely improves cognitive function in Malay and Chinese people with mild cognitive impairment (MCI) associated with age.

Study 1 Design:
   * Randomized, double-blind, placebocontrolled clinical trial
   * 36 low-socioeconomic-status elderly Malay and Chinese subjects with MCI (mean age 66.4 yrs +/- 5. yrs in the DHA¹ group and 63.5 +/- 3 yrs in the placebo group)
   * Took the took 1.3 g DHA¹ + 0.45 g EPA² daily or a corn oil placebo for 12 months.

Study 1 Assessments:
Before and after treatment all participants were assessed for brain function and overall health using a variety tests as follows:
   * Primary endpoints
      - Memory
      - Executive function and attention
      - Psychomotor speed
      - Visiospatial skills
      - Depression
      - Dementia and Global Cognitive function

   * Secondary endpoints
      - Safety and tolerability

   * The active DHA¹ product provided was the high DHA¹ oil that is the lead active ingredient in Efalex Active 50+ and Efalex Concentrate.

Conclusion
DHA¹ supplementation significantly improved memory function in people with mild cognitive impairment associated with age.

* This was the first study specifically designed to measure cognitive improvements (rather than prevention of decline) in people with mild cognitive impairment.

FOOT NOTES
1. DHA (Docosahexaenoic Acid) an important Omega-3 nutrient that contributes to the maintenance of normal brain function and normal vision. EPA and DHA also contribute to the normal function of the heart.
2. EPA (Eicosapentaenoic Acid) an important Omega-3 fatty acid required for a number of functions in the body that regulate all responses together with other LCPUFAs³. EPA and DHA also contribute to the normal function of the heart. 
3. LCPUFAs (Long-chain polyunsaturated fatty acids)